tiprankstipranks
Advertisement
Advertisement
Analyst Reiterates Buy on LENZ Amid Strong Early Commercial Execution and Durable Demand Signals
PremiumRatingsAnalyst Reiterates Buy on LENZ Amid Strong Early Commercial Execution and Durable Demand Signals
23d ago
Lenz Therapeutics price target lowered to $38 from $48 at H.C. Wainwright
Premium
The Fly
Lenz Therapeutics price target lowered to $38 from $48 at H.C. Wainwright
23d ago
Lenz Therapeutics downgraded to Neutral from Overweight at Piper Sandler
Premium
The Fly
Lenz Therapeutics downgraded to Neutral from Overweight at Piper Sandler
23d ago
LENZ Therapeutics: Early VIZZ Launch Traction Supports Buy Rating Despite Trimmed Near‑Term Outlook
PremiumRatingsLENZ Therapeutics: Early VIZZ Launch Traction Supports Buy Rating Despite Trimmed Near‑Term Outlook
1M ago
Lenz Therapeutics price target lowered to $48 from $56 at H.C. Wainwright
Premium
The Fly
Lenz Therapeutics price target lowered to $48 from $56 at H.C. Wainwright
1M ago
Lenz Therapeutics announces submission of MAA to U.K.’s MHRA for VIZZ 1.44%
Premium
The Fly
Lenz Therapeutics announces submission of MAA to U.K.’s MHRA for VIZZ 1.44%
1M ago
Lenz Therapeutics reports Q4 EPS ($1.16), consensus (90c)
PremiumThe FlyLenz Therapeutics reports Q4 EPS ($1.16), consensus (90c)
2M ago
Is LENZ a Buy, Before Earnings?
Premium
Pre-Earnings
Is LENZ a Buy, Before Earnings?
2M ago
Lenz Therapeutics announces submission of MAA to EMA for VIZ
Premium
The Fly
Lenz Therapeutics announces submission of MAA to EMA for VIZ
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100